{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:46:53Z","timestamp":1790660813340,"version":"4.1.0"},"reference-count":96,"publisher":"The Endocrine Society","issue":"5","license":[{"start":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T00:00:00Z","timestamp":1668988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Postmenopausal hyperandrogenism is a condition caused by relative or absolute androgen excess originating from the ovaries and\/or the adrenal glands. Hirsutism, in other words, increased terminal hair growth in androgen-dependent areas of the body, is considered the most effective measure of hyperandrogenism in women. Other symptoms can be acne and androgenic alopecia or the development of virilization, including clitoromegaly. Postmenopausal hyperandrogenism may also be associated with metabolic disorders such as abdominal obesity, insulin resistance, and type 2 diabetes. Mild hyperandrogenic symptoms can be due to relative androgen excess associated with menopausal transition or polycystic ovary syndrome, which is likely the most common cause of postmenopausal hyperandrogenism. Virilizing symptoms, on the other hand, can be caused by ovarian hyperthecosis or an androgen-producing ovarian or adrenal tumor that could be malignant. Determination of serum testosterone, preferably by tandem mass spectrometry, is the first step in the endocrine evaluation, providing important information on the degree of androgen excess. Testosterone &amp;gt;5 nmol\/L is associated with virilization and requires prompt investigation to rule out an androgen-producing tumor in the first instance. To localize the source of androgen excess, imaging techniques are used, such as transvaginal ultrasound or magnetic resonance imaging (MRI) for the ovaries and computed tomography and MRI for the adrenals. Bilateral oophorectomy or surgical removal of an adrenal tumor is the main curative treatment and will ultimately lead to a histopathological diagnosis. Mild to moderate symptoms of androgen excess are treated with antiandrogen therapy or specific endocrine therapy depending on diagnosis. This review summarizes the most relevant causes of hyperandrogenism in postmenopausal women and suggests principles for clinical investigation and treatment.<\/jats:p>","DOI":"10.1210\/clinem\/dgac673","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T16:45:48Z","timestamp":1669049148000},"page":"1243-1253","source":"Crossref","is-referenced-by-count":59,"title":["Approach to Investigation of Hyperandrogenism in a Postmenopausal Woman"],"prefix":"10.1210","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6481-6277","authenticated-orcid":false,"given":"Angelica Lind\u00e9n","family":"Hirschberg","sequence":"first","affiliation":[{"name":"Department of Women's and Children's Health, Karolinska Institutet , Stockholm SE-171 76 , Sweden"},{"name":"Department of Gynecology and Reproductive Medicine, Karolinska University Hospital , Stockholm SE-171 76 , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2022,11,21]]},"reference":[{"issue":"3","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1365-2133.1977.tb15179.x","article-title":"Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex","volume":"97","author":"Ludwig","year":"1977","journal-title":"Br J Dermatol"},{"issue":"3","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1210\/jc.2017-02426","article-title":"Causes, patterns, and severity of androgen excess in 1205 consecutively recruited women","volume":"103","author":"Elhassan","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1210\/jc.2005-0212","article-title":"Androgen levels in adult females: changes with age, menopause, and oophorectomy","volume":"90","author":"Davison","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0300-595X(86)80021-4","article-title":"Adrenal and gonadal androgen secretion in normal females","volume":"15","author":"Longcope","year":"1986","journal-title":"Clin Endocrinol Metab"},{"key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jsbmb.2016.12.007","article-title":"Androgens in women are essentially made from DHEA in each peripheral tissue according to intracrinology","volume":"168","author":"Labrie","year":"2017","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"5","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s41574-020-0336-x","article-title":"11-Oxygenated androgens in health and disease","volume":"16","author":"Turcu","year":"2020","journal-title":"Nat Rev Endocrinol"},{"issue":"7","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1210\/jc.2018-02527","article-title":"11-Oxygenated C19 steroids do not decline with age in women","volume":"104","author":"Nanba","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1210\/jc.2016-3285","article-title":"11-Oxygenated C19 steroids are the predominant androgens in polycystic ovary syndrome","volume":"102","author":"O\u2019Reilly","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1530\/EJE-15-1181","article-title":"Adrenal-derived 11-oxygenated 19-carbon steroids are the dominant androgens in classic 21-hydroxylase deficiency","volume":"174","author":"Turcu","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1210\/jcem-53-1-58","article-title":"Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma","volume":"53","author":"Dunn","year":"1981","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S0015-0282(16)60609-X","article-title":"Decreasing serum levels of sex hormone-binding globulin around the menopause and temporary relation to changing levels of ovarian steroids, as demonstrated in a longitudinal study","volume":"51","author":"Gershagen","year":"1989","journal-title":"Fertil Steril"},{"issue":"8","key":"2023041309391336700_","first-page":"2832","article-title":"A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition","volume":"85","author":"Burger","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/gme.0b013e318185e249","article-title":"Relative androgen excess during the menopausal transition predicts incident metabolic syndrome in midlife women: study of women's health across the nation","volume":"16","author":"Torr\u00e9ns","year":"2009","journal-title":"Menopause"},{"issue":"1","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0022-5347(05)64023-2","article-title":"Adrenocortical carcinoma: diagnosis, evaluation and treatment","volume":"169","author":"Ng","year":"2003","journal-title":"J Urol"},{"issue":"5","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1093\/humupd\/dmx014","article-title":"Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: an update with a special focus on adolescent and adult women","volume":"23","author":"Carmina","year":"2017","journal-title":"Hum Reprod Update"},{"issue":"1","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"101521","DOI":"10.1016\/j.beem.2021.101521","article-title":"Epidemiology and mortality of Cushing's syndrome","volume":"35","author":"Hakami","year":"2021","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1741-7015-8-41","article-title":"Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan","volume":"8","author":"Teede","year":"2010","journal-title":"BMC Med"},{"key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"16057","DOI":"10.1038\/nrdp.2016.57","article-title":"Polycystic ovary syndrome","volume":"11","author":"Azziz","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/humrep\/deh098","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)","volume":"19","author":"Rotterdam ESHRE\/ASRM-Sponsored PCOS consensus workshop group","year":"2004","journal-title":"Hum Reprod"},{"issue":"12","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1210\/jc.2013-2350","article-title":"Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline","volume":"98","author":"Legro","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/S0015-0282(03)00152-3","article-title":"Aging women with polycystic ovary syndrome who achieve regular menstrual cycles have a smaller follicle cohort than those who continue to have irregular cycles","volume":"79","author":"Elting","year":"2003","journal-title":"Fertil Steril"},{"key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1210\/jc.2009-0839","article-title":"Criteria for polycystic ovarian morphology in polycystic ovary syndrome as a function of age","volume":"94","author":"Alsamarai","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.fertnstert.2011.09.002","article-title":"The phenotype of polycystic ovary syndrome ameliorates with aging","volume":"96","author":"Brown","year":"2011","journal-title":"Fertil Steril"},{"issue":"7","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1093\/humrep\/deq088","article-title":"Is polycystic ovary syndrome an exception for reproductive aging?","volume":"25","author":"Tehrani","year":"2010","journal-title":"Hum Reprod"},{"issue":"5","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.fertnstert.2018.08.021","article-title":"Beyond fertility: polycystic ovary syndrome and long-term health","volume":"110","author":"Cooney","year":"2018","journal-title":"Fertil Steril"},{"issue":"2","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1210\/clinem\/dgaa840","article-title":"Reproductive hormones and anthropometry: a follow-up of PCOS and controls from perimenopause to older than 80 years","volume":"106","author":"Forslund","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/humrep\/dex078","article-title":"Mass spectrometry, immunoassay and valid steroid measurements in reproductive medicine and science","volume":"32","author":"Handelsman","year":"2017","journal-title":"Hum Reprod"},{"issue":"5","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1210\/er.2018-00020","article-title":"Circulating testosterone as the hormonal basis of sex differences in athletic performance","volume":"39","author":"Handelsman","year":"2018","journal-title":"Endocr Rev"},{"issue":"2","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"R79","DOI":"10.1530\/EJE-14-0468","article-title":"Hyperandrogenism after menopause","volume":"172","author":"Markopoulos","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1210\/jc.2010-2959","article-title":"Reproductive hormone levels and anthropometry in postmenopausal women with polycystic ovary syndrome (PCOS): a 21-year follow-up study of women diagnosed with PCOS around 50 years ago and their age-matched controls","volume":"96","author":"Schmidt","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1210\/jc.2010-0130","article-title":"Hyperandrogenism in women with polycystic ovary syndrome persists after menopause","volume":"96","author":"Markopoulos","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1210\/jc.2017-02421","article-title":"High androgens in postmenopausal women and the risk for atherosclerosis and cardiovascular disease: The Rotterdam Study","volume":"103","author":"Meun","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1373\/clinchem.2018.290825","article-title":"Diagnostic thresholds for androgen-producing tumors or pathologic hyperandrogenism in women by use of total testosterone concentrations measured by liquid chromatography-tandem mass spectrometry","volume":"64","author":"Sharma","year":"2018","journal-title":"Clin Chem"},{"issue":"5","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2217\/WHE.09.39","article-title":"Polycystic ovary syndrome, obesity and reproductive implications","volume":"5","author":"Hirschberg","year":"2009","journal-title":"Womens Health (Lond)"},{"issue":"6","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1210\/er.2011-1034","article-title":"Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications","volume":"33","author":"Diamanti-Kandarakis","year":"2012","journal-title":"Endocr Rev"},{"key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2147\/IJWH.S344542","article-title":"Effect of sex hormone-binding globulin on polycystic ovary syndrome: mechanisms, manifestations, genetics, and treatment","volume":"14","author":"Xing","year":"2022","journal-title":"Int J Womens Health"},{"issue":"2","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2337\/diabetes.51.2.484","article-title":"A unique defect in the regulation of visceral fat cell lipolysis in the polycystic ovary syndrome as an early link to insulin resistance","volume":"51","author":"Ek","year":"2002","journal-title":"Diabetes"},{"issue":"8","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1080\/09513590.2021.1903419","article-title":"Hyperthecosis: an underestimated nontumorous cause of hyperandrogenism","volume":"37","author":"Meczekalski","year":"2021","journal-title":"Gynecol Endocrinol"},{"issue":"5 Pt 2","key":"2023041309391336700_","first-page":"893","article-title":"Postmenopausal hyperthecosis: functional dysregulation of androgenesis in climacteric ovary","volume":"99","author":"Krug","year":"2002","journal-title":"Obstet Gynecol"},{"issue":"5","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/uog.6131","article-title":"Ovarian hyperthecosis on grayscale and color Doppler ultrasound","volume":"32","author":"Rousset","year":"2008","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"1","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1530\/EJE-17-0111","article-title":"Discriminating between virilizing ovary tumors and ovary hyperthecosis in postmenopausal women: clinical data, hormonal profiles and image studies","volume":"177","author":"Yance","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/0002-9378(86)90676-9","article-title":"Hyperinsulinemia in hyperthecosis of the ovaries","volume":"154","author":"Nagamani","year":"1986","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1046\/j.1365-2265.1997.1050916.x","article-title":"Ovarian hyperthecosis, diabetes and hirsuties in post-menopausal women","volume":"46","author":"Barth","year":"1997","journal-title":"Clin Endocrinol"},{"issue":"1","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1210\/jcem-67-1-144","article-title":"Hyperinsulinemia and stromal luteinization of the ovaries in postmenopausal women with endometrial cancer","volume":"67","author":"Nagamani","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.humpath.2016.09.021","article-title":"Association of ovarian hyperthecosis with endometrial polyp, endometrial hyperplasia, and endometrioid adenocarcinoma in postmenopausal women: a clinicopathological study of 238 cases","volume":"59","author":"Zhang","year":"2017","journal-title":"Hum Pathol"},{"issue":"2","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"R81","DOI":"10.1530\/ERC-18-0429","article-title":"Androgen excess in breast cancer development: implications for prevention and treatment","volume":"26","author":"Secreto","year":"2019","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"587","DOI":"10.7863\/jum.2009.28.5.587","article-title":"Ovarian stromal hyperthecosis: sonographic features and histologic associations","volume":"28","author":"Brown","year":"2009","journal-title":"J Ultrasound Med"},{"issue":"2","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0002-9378(72)90137-8","article-title":"Familial ovarian hyperthecosis","volume":"112","author":"Fienberg","year":"1972","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S0015-0282(98)00464-6","article-title":"Increased expression of messenger ribonucleic acid encoding cytochrome P450 cholesterol side-chain cleavage and P450 17\u03b1-hydroxylase enzymes in ovarian hyperthecosis","volume":"71","author":"Nagamani","year":"1999","journal-title":"Fertil Steril"},{"issue":"1","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0015-0282(16)56810-1","article-title":"The climacteric ovary as a functional gonadotropin-driven androgen-producing gland","volume":"62","author":"Adashi","year":"1994","journal-title":"Fertil Steril"},{"issue":"6","key":"2023041309391336700_","first-page":"1789","article-title":"Type B insulin resistance masquerading as ovarian hyperthecosis","volume":"102","author":"Brown","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2023041309391336700_","first-page":"286","article-title":"Androblastoma of the ovary: clinical, diagnostic and histopathologic features","volume":"24","author":"Fleckenstein","year":"2001","journal-title":"Onkologie"},{"key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000494906","article-title":"Androgen-secreting ovarian tumors","volume":"53","author":"Macut","year":"2019","journal-title":"Front Horm Res"},{"issue":"8","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/00000478-198508000-00001","article-title":"Ovarian Sertoli-Leydig cell tumors. A clinicopathological analysis of 207 cases","volume":"9","author":"Young","year":"1985","journal-title":"Am J Surg Pathol"},{"key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/1477-7819-11-142","article-title":"Ovarian granulosa cell tumors: a retrospective study of 27 cases and a review of the literature","volume":"11","author":"Sekkate","year":"2013","journal-title":"World J Surg Oncol"},{"issue":"21","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1056\/NEJM199311183292104","article-title":"Elevated serum inhibin concentrations in postmenopausal women with ovarian tumors","volume":"329","author":"Healy","year":"1993","journal-title":"New Engl J Med"},{"issue":"10","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1053\/hupa.2000.18498","article-title":"Anti-M\u00fcllerian hormone is a specific marker of Sertoli- and granulosa-cell origin in gonadal tumors","volume":"31","author":"Rey","year":"2000","journal-title":"Hum Pathol"},{"issue":"6","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S0039-6060(03)00410-0","article-title":"Androgen-secreting adrenal tumors","volume":"134","author":"Cordera","year":"2003","journal-title":"Surgery"},{"issue":"6","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.surg.2004.06.046","article-title":"Profile and outcome of pure androgen-secreting adrenal tumors in women: experience of 21 cases","volume":"136","author":"Moreno","year":"2004","journal-title":"Surgery"},{"key":"2023041309391336700_","volume-title":"Endotext [Internet]","author":"Angelousi","year":"2000"},{"issue":"10108","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1016\/S0140-6736(17)31431-9","article-title":"Congenital adrenal hyperplasia","volume":"390","author":"El-Maouche","year":"2017","journal-title":"Lancet"},{"issue":"11","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1210\/jc.2018-01865","article-title":"Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an endocrine society* clinical practice guideline","volume":"103","author":"Speiser","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1067\/mob.2000.108020","article-title":"21-Hydroxylase-deficient nonclassic adrenal hyperplasia is a progressive disorder: a multicenter study","volume":"183","author":"Moran","year":"2000","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1210\/jc.2003-031122","article-title":"Androgen excess in women: experience with over 1000 consecutive patients","volume":"89","author":"Azziz","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"9996","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0140-6736(14)61375-1","article-title":"Cushing's syndrome","volume":"386","author":"Lacroix","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"M33","DOI":"10.1530\/EJE-15-0464","article-title":"Cushing's syndrome: update on signs, symptoms and biochemical screening","volume":"173","author":"Nieman","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1046\/j.1365-2265.2000.01117.x","article-title":"How common are polycystic ovaries and the polycystic ovarian syndrome in women with Cushing's Syndrome?","volume":"53","author":"Kaltsas","year":"2000","journal-title":"Clin Endocrinol"},{"issue":"5","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1210\/jc.2008-0125","article-title":"The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline","volume":"93","author":"Nieman","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1210\/jc.2018-00241","article-title":"Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society Clinical Practice Guideline","volume":"103","author":"Martin","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"1-2","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.eplepsyres.2011.07.006","article-title":"A meta-analysis of polycystic ovary syndrome in women taking valproate for epilepsy","volume":"97","author":"Hu","year":"2011","journal-title":"Epilepsy Res"},{"issue":"2","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1210\/en.2003-0940","article-title":"Valproate potentiates androgen biosynthesis in human ovarian theca cells","volume":"145","author":"Nelson-DeGrave","year":"2004","journal-title":"Endocrinology"},{"key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s13023-014-0205-6","article-title":"Frequency of the virilising effects of attenuated androgens reported by women with hereditary angioedema","volume":"9","author":"Zotter","year":"2014","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"476","DOI":"10.23736\/S0391-1977.18.02810-9","article-title":"Adverse effects of doping with anabolic androgenic steroids in competitive athletics, recreational sports and bodybuilding","volume":"43","author":"Vorona","year":"2018","journal-title":"Minerva Endocrinol"},{"key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.bpobgyn.2016.05.003","article-title":"Androgen excess: investigations and management","volume":"37","author":"Lizneva","year":"2016","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1210\/jcem-21-11-1440","article-title":"Clinical assessment of body hair growth in women","volume":"21","author":"Ferriman","year":"1961","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/humupd\/dmp024","article-title":"Visually scoring hirsutism","volume":"16","author":"Yildiz","year":"2010","journal-title":"Hum Reprod Update"},{"issue":"3","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.fertnstert.2018.05.004","article-title":"; international PCOS network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome","volume":"110","author":"Teede","year":"2018","journal-title":"Fertil Steril"},{"key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejogrb.2017.01.054","article-title":"Is acne a sign of androgen excess disorder or not?","volume":"211","author":"Uysal","year":"2017","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"1","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1046\/j.1523-1747.2003.12168.x","article-title":"Androgenetic alopecia in women","volume":"8","author":"Price","year":"2003","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"5","key":"2023041309391336700_","first-page":"562","article-title":"The clitoral index: a bioassay of androgenic stimulation","volume":"54","author":"Tagatz","year":"1979","journal-title":"Obstet Gynecol"},{"issue":"1","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ecl.2020.12.002","article-title":"Postmenopausal hyperandrogenism: evaluation and treatment strategies","volume":"50","author":"Zaman","year":"2021","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"5","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1530\/EJE-11-0542","article-title":"Impact of clinical, hormonal, radiological, and immunohistochemical studies on the diagnosis of postmenopausal hyperandrogenism","volume":"165","author":"Sarfati","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"593","DOI":"10.4103\/ijem.IJEM_553_19","article-title":"Dynamic testing for evaluation of adrenal and gonadal function in pediatric and adult endocrinology: an overview","volume":"23","author":"Goyal","year":"2019","journal-title":"Indian J Endocrinol Metab"},{"issue":"7","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1080\/09513590.2021.1897099","article-title":"Dexamethasone suppression test versus selective ovarian and adrenal vein catheterization in identifying virilizing tumors in postmenopausal hyperandrogenism - a systematic review and meta-analysis","volume":"37","author":"Tng","year":"2021","journal-title":"Gynecol Endocrinol"},{"issue":"3","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1006\/gyno.2000.5783","article-title":"Ovarian volume related to age","volume":"77","author":"Pavlik","year":"2000","journal-title":"Gynecol Oncol"},{"issue":"6","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1053\/j.seminoncol.2010.10.016","article-title":"Androgen- and estrogen-secreting adrenal cancer","volume":"37","author":"Cavlan","year":"2010","journal-title":"Semin Oncol"},{"issue":"1","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/cen.13492","article-title":"Clinical case seminar: postmenopausal androgen excess-challenges in diagnostic work-up and management of ovarian thecosis","volume":"88","author":"Mamoojee","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1365-2265.2012.04438.x","article-title":"No metabolic impact of surgical normalization of hyperandrogenism in postmenopausal women with ovarian androgen-secreting tumours","volume":"78","author":"Pelusi","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1210\/jc.2010-1991","article-title":"Gonadotropin-releasing hormone agonist treatment in postmenopausal women with hyperandrogenism of ovarian origin","volume":"96","author":"Vollaard","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1080\/17425255.2020.1789591","article-title":"Tolerability considerations for gonadotropin-releasing hormone analogues for endometriosis","volume":"16","author":"Della Corte","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"5","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.fertnstert.2019.09.037","article-title":"Short- and long-term impact of gonadotropin-releasing hormone analogue treatment on bone loss and fracture","volume":"112","author":"Sauerbrun-Cutler","year":"2019","journal-title":"Fertil Steril"},{"issue":"4","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1530\/EJE-13-0585","article-title":"Therapy in endocrine disease: treatment of hirsutism in the polycystic ovary syndrome","volume":"170","author":"Pasquali","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.jaad.2018.08.061","article-title":"Androgens in women: hormone-modulating therapies for skin disease","volume":"80","author":"Azarchi","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"2023041309391336700_","article-title":"Metformin versus the combined oral contraceptive pill for hirsutism, acne, and menstrual pattern in polycystic ovary syndrome","volume":"8","author":"Fraison","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"2023041309391336700_","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1210\/jc.2017-02052","article-title":"Treatment options for hirsutism: a systematic review and network meta-analysis","volume":"103","author":"Barrionuevo","year":"2018","journal-title":"J Clin Endocrinol Metab"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgac673\/49056889\/dgac673.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/5\/1243\/49873849\/dgac673.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/5\/1243\/49873849\/dgac673.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T09:06:11Z","timestamp":1701421571000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/108\/5\/1243\/6835644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,21]]},"references-count":96,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,11,21]]},"published-print":{"date-parts":[[2023,4,13]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgac673","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5,1]]},"published":{"date-parts":[[2022,11,21]]}}}